Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Fig. 2

Best tumour responses in patients with lymphoma evaluable for response. Best tumour responses as assessed by sum of product diameters of target lesions in evaluable patients with lymphoma (in percentage) for CXD101 doses of ≥16 mg twice daily in patients shown according to baseline tumour HR23B status by immunohistochemistry and best disease response by Cheson et al. [21]. Two patients (1 FL and 1cHL) were not evaluable for objective response but clinically had a best response of progressive disease. * denotes patients with reduction in target lesions but clear progression of non-target lesions and / or new lesions. cHL classic Hodgkin lymphoma; GZL grey zone lymphoma; AITL angioimmunoblastic T-cell lymphoma; PTCL Peripheral T-cell lymphoma NOS; FL follicular lymphoma

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us